Skip to content

JBIO JBIO Net unrealized losses

Net unrealized losses at other companies

Seaboard logo
SeaboardSEB
-$5M+58.3%
NewAmsterdam Pharma Company logo
NewAmsterdam Pharma CompanyNAMS
-$572K-1,633%
Savara logo
SavaraSVRA
-$247K-60.4%
Root, Inc. logo
Root, Inc.ROOT
-$3.5M-217%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
-$1.1M-535%
Twist Bioscience Corporation logo
Twist Bioscience CorporationTWST
-$85K-383%

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.33B+318%
Enterprise value$1.28B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesTradingUnrealizedGainLoss.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's net unrealized losses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's net unrealized losses?
JBIO (JBIO) reported net unrealized losses of -$473K in Q1 2026.
What does net unrealized losses mean?
This metric represents the change in the market value of trading debt securities held by the company that have not yet been sold. It reflects the unrealized impact of interest rate changes and credit spread fluctuations on the company's investment portfolio. These gains or losses are typically recognized in the income statement as part of non-operating activities.